This past April, CURA Diagnostics proudly participated in two leading industry conferences: the Rx and Illicit Drug Summit and the Governor's Institute.

For over 15 years, the Rx and Illicit Drug Summit has been a driving force in the fight against the opioid and addiction crisis, bringing together stakeholders to share groundbreaking ideas and forge strategy with public officials. This year's Summit took place in Nashville, Tennessee, with over 3000 attendees and all 50 states represented. CURA's Vice President of Sales, Paul Mincey, attended the Summit, where he highlighted the organization's innovative solutions.

Paul Mincey (right) at CURA Diagnostic's booth at the RX and Illicit Drug Summit in Nashville, TN

CURA's booth at the Governor's Institute in Asheville, NC

Representing CURA, Paul also attended this year's Governor's 

Representing CURA, Paul also attended this year's Governor's Institute in Asheville, North Carolina. The Governor's Institute works collaboratively with partners to deliver physician-focused initiatives that equip clinicians in both primary care and specialty settings to better prevent, identify, and treat substance use disorders. At the conference, CURA highlighted its integrated testing, laboratory, and consulting solutions, spanning collection through confirmation, designed to streamline toxicology workflows and support more effective responses to substance use crises.

Pictured below is Paul with Dr. Stephen Loyd, a speaker at both conferences and a nationally recognized leader in addiction medicine. Dr. Loyd uses his platform to combat the opioid crisis both within his community and across the country, where his work served as inspiration for Michael Keaton's character in the Hulu series Dopesick. Through his advocacy, Dr. Loyd continues to raise awareness about the dangers of fentanyl and the broader opioid epidemic, as well as the science behind medication-assisted therapies.

Paul (left) with Dr. Stephen Loyd (right) at the Governor's Institute

CURA Diagnostics' participation reflects its dual commitment to addressing the substance use epidemic, and advancing community awareness through industry collaboration and education, while developing innovative laboratory solutions to transform care.

The company will continue its engagement this spring at the American Society of Addiction Medicine (ASAM, April 23–26) and National Drug & Alcohol Screening Association (NDASA, April 27–30) 2026 conferences, followed by the Association for Diagnostics & Laboratory Medicine Clinical Lab Expo (ADLM, July 26–30) and the Society of Forensic Toxicologists Annual Meeting (SOFT, September 19–24).